Synthetic cannabinoids

American Journal of the Medical Sciences

Volumn 350, Issue 1, 2015, Pages 59-62

  Mills, Brooke ^a   Yepes, Andres ^a   Nugent, Kenneth ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

Abuse; Acute kidney injury; Cannabinoids; Synthetic marijuana; Toxicity

Indexed keywords

CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABIS; DRONABINOL; SYNTHETIC CANNABINOID; UNCLASSIFIED DRUG; CANNABINOID RECEPTOR AGONIST; DESIGNER DRUG;

ACUTE KIDNEY FAILURE; AGITATION; CANNABIS ADDICTION; CANNABIS USE; CONFUSION; DELUSION; DIZZINESS; DROWSINESS; HALLUCINATION; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; IRRITABILITY; MULTIPLE DRUG ABUSE; NAUSEA; REVIEW; TACHYCARDIA; THORAX PAIN; TOXICITY; VERTIGO; CHEMICALLY INDUCED; PSYCHOMOTOR AGITATION; SUBSTANCE-RELATED DISORDERS;

ACUTE KIDNEY INJURY; CANNABINOID RECEPTOR AGONISTS; CANNABINOIDS; CHEST PAIN; DESIGNER DRUGS; DRONABINOL; HALLUCINATIONS; HUMANS; HYPERTENSION; IRRITABLE MOOD; PSYCHOMOTOR AGITATION; SUBSTANCE-RELATED DISORDERS; TACHYCARDIA; VERTIGO;

EID: 84936881568     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0000000000000466     Document Type: Review

References (45)

1. Bonar EE, Ashrafioun L, Ilgen MA. Synthetic cannabinoid use among patients in residential substance use disorder treatment: prevalence, motives, and correlates. Drug Alcohol Depend 2014;143:268-71.
2. Gunderson EW, Haughey HM, Ait-Daoud N, et al. "Spice" and "K2" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict 2012;21:320-6.
3. Jarbe TU, Gifford RS. "Herbal incense": designer drug blends as cannabimimetics and their assessment by drug discrimination and other in vivo bioassays. Life Sci 2014;97:64-71.
4. Zuba D, Byrska B, Maciow M. Comparison of "herbal highs" composition. Anal Bioanal Chem 2011;400:119-26.
5. Fattore L, Fratta W. Beyond THC: The new Generation of cannabi-noid designer drugs. Front Behav Neurosci 2011;5:60.
6. Vardakou I, Pistos C, Spiliopoulou C. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 2010;197:157-62.
7. Vandrey R, Dunn KE, Fry JA, et al. A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend 2012;120:238-41.
8. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997;74:129-80.
9. Castaneto MS, Gorelick DA, Desrosiers NA, et al. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 2014;144:12-41.
10. Fantegrossi WE, Moran JH, Radominska-Pandya A, et al. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to delta(9)-THC: mechanism underlying greater toxicity? Life Sci 2014; 97:45-54.
11. Sharma P, Murthy P, Bharath MM. Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiatry 2012;7:149-56.
12. Chimalakonda KC, Seely KA, Bratton SM, et al. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metab Dispos 2012;40:2174-84.
13. Patton AL, Seely KA, Chimalakonda KC, et al. Targeted metabolo-mic approach for assessing human synthetic cannabinoid exposure and pharmacology. Anal Chem 2013;85:9390-9.
14. Seely KA, Prather PL, James LP, et al. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol Interv 2011; 11:36-51.
15. Brents LK, Zimmerman SM, Saffell AR, et al. Differential drug-drug interactions of the synthetic Cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy. J Pharmacol Exp Ther 2013;346:350-61.
16. Uchiyama N, Kikura-Hanajiri R, Goda Y. Identification of a novel cannabimimetic phenylacetylindole, cannabipiperidiethanone, as a designer drug in a herbal product and its affinity for cannabinoid CB(1) and CB(2) receptors. Chem Pharm Bull (Tokyo) 2011;59:1203-5.
17. Rosenbaum CD, Carreiro SP, Babu KM. Here today, gone tomorrow.. and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. J Med Toxicol 2012;8:15-32.
18. Barratt MJ, Cakic V, Lenton S. Patterns of synthetic cannabinoid use in Australia. Drug Alcohol Rev 2013;32:141-6.
19. Winstock AR, Barratt MJ. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend 2013;131:106-11.
20. Forrester MB, Kleinschmidt K, Schwarz E, et al. Synthetic cannabinoid and marijuana exposures reported to poison centers. Hum Exp Toxicol 2012;31:1006-11.
21. Forrester MB. Adolescent synthetic cannabinoid exposures reported to Texas poison centers. Pediatr Emerg Care 2012;28:985-9.
22. Gurney SMR, Scott SK, Kacinko SL, et al. Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Sci Rev 2014;26:53.
23. Schep L, Slaughter R, Hudson S, et al. Delayed seizure-like activity following analytically confirmed use of previously unreported synthetic cannabinoid analogues. Hum Exp Toxicol 2015; 34:557-60.
24. Smith DL, Roberts C. Synthetic marijuana use and development of catatonia in a 17-year-old male. Minn Med 2014;97:38.
25. Meijer KA, Russo RR, Adhvaryu DV. Smoking synthetic marijuana leads to self-mutilation requiring bilateral amputations. Orthopedics 2014;37:391-4.
26. Rahmani M, Paul S, Nguyen ML. Treatment of refractory substance-induced psychosis in adolescent males with a genetic predisposition to mental illness. Int J Adolesc Med Health 2014;26:297-301.
27. Celofiga A, Koprivsek J, Klavz J. Use of synthetic cannabinoids in patients with psychotic disorders: case series. J Chem Depend Treat 2014;10:163-73.
28. Glue P, Al-Shaqsi S, Hancock D, et al. Hospitalisation associated with use of the synthetic cannabinoid K2. N Z Med J 2013;126:18-23.
29. Patton AL, Chimalakonda CK, Moran CL, et al. K2 toxicity: fatal case of psychiatric complications following AM2201 exposure. J Forensic Sci 2013;58:1676-80.
30. Saito T, Namera A, Miura N, et al. A fatal case of MAM-2201 poisoning. Forensic Toxicol 2013;31:333-7.
31. Takematsu M, Hoffman RS, Nelson LS, et al. A case of acute cerebral ischemia following inhalation of a synthetic cannabinoid. Clin Toxicol (Phila) 2014;52:973-5.
32. McKeever RG, Vearrier D, Jacobs D, et al. K2-Not the spice of Life; synthetic cannabinoids and ST Elevation myocardial infarction: a case report. J Med Toxicol 2015;11:129-31.
33. Ibrahim S, Al-Saffar F, Wannenburg T. A unique case of cardiac arrest following K2 abuse. Case Rep Cardiol 2014;2014:120607. doi: 10.1155/2014/120607. Epub 2014 May 25.
34. Ukaigwe A, Karmacharya P, Donato A. A gut gone to pot: a case of cannabinoid hyperemesis syndrome due to K2, a synthetic cannabinoid. Case Rep Emerg Med 2014;2014:167098.
35. Buser GL, Gerona RR, Horowitz BZ, et al. Acute kidney injury associated with smoking synthetic cannabinoid. Clin Toxicol (Phila) 2014;52:664-73.
36. Bhanushali GK, Jain G, Fatima H, et al. AKI associated with synthetic cannabinoids: a case series. Clin J Am Soc Nephrol 2013;8:523-6.
37. CDC. Acute kidney injury associated with synthetic cannabinoid use-multiple states, 2012. MMWR Morb Mortal Wkly Rep 2013; 62: 93-8.
38. Schneberk T, Sterling GP, Valenzuela R, et al. 390 "A Little Dab Will Do Ya": an emergency department case series Related to a new form of "High-Potency" marijuana known as "Wax". Ann Emerg Med 2014;64:S139.
39. Lapoint JD, Nelson LS. Synthetic cannabinoids: the newest, almost illicit drug of abuse. Emerg Med 2011;43:26-8.
40. Rech MA, Donahey E, Cappiello Dziedzic JM, et al. New drugs of abuse. Pharmacotherapy 2015;35:189-97.
41. Kersten BP, McLaughlin ME. Toxicology and management of novel psychoactive drugs. J Pharm Pract 2015;28:50-65.
42. Allsop DJ, Norberg MM, Copeland J, et al. The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend 2011;119:123-9.
43. Hirvonen J, Goodwin RS, Li CT, et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry 2012;17:642-9.
44. Vandrey R, Stitzer ML, Mintzer MZ, et al. The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. Drug Alcohol Depend 2013;128:64-70.
45. Zimmermann US, Winkelmann PR, Pilhatsch M, et al. Withdrawal phenomena and dependence syndrome after the consumption of "spice gold". Dtsch Ärztebl Int 2009;106:464-7.